Orthofix Medical Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Orthofix reported Q2 2026 pro forma net sales of $210.9M (+5% YoY constant currency), with Global Spine Fixation and Global Limb Reconstruction each delivering double-digit growth. Adjusted EBITDA was $20.1M (9.6% margin). The company raised full-year 2026 net sales guidance to $845–$855M (from $838–$848M) and adjusted EBITDA guidance to $95–$98M (from $90–$93M), citing Medicare reimbursement restoration for bone growth stimulators, cost optimization, and strong momentum in key growth platforms.
Why this rating
Guidance raise modest (~0.8% upside); real growth in core segments. At $440M market cap, ~$10M EBITDA upside is ~2–3% value accretion. Operational progress meaningful but company still GAAP-unprofitable; FCF remains negative.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.